Stoke Therapeutics accelerates EMPEROR enrollment, expects Phase 3 data in mid-2027, cash $391.7M

Stoke Therapeutics, Inc.

Enrollment of 150 patients in Phase 3 EMPEROR study expected to complete in Q2 2026, accelerated from prior timeline.
Phase 3 data readout planned for mid-2027; rolling NDA submission to initiate in first half 2027.
FDA multidisciplinary meeting held; no immediate program changes, but discussions ongoing for expedited pathways.
Cash, equivalents and marketable securities $391.7M as of Dec 31, 2025; plus Biogen proceeds funds operations into 2028.
Nearly 330 potential study candidates identified globally; ~60 in screening, ~60 randomized/dosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.